CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
NVDX3drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05987033
NCT05987033Phase 2Completed
CompareCT.gov

A First-in-human Proof-of-concept Study With NVDX3, an Osteogenic Implant of Human Allogenic Origin, in the Treatment of Distal Radius Fractures in Adults.

Novadip Biosciences·interventional·Posted Aug 14, 2023·Updated Jan 28, 2026

In Brief

A Phase 2 clinical trial evaluating NVDX3 for Distal Radius Fractures. Completed, enrolled 11 participants across 1 site.

Detailed Summary

Prospective, single arm, monocentric clinical study to test NVDX3 in patients suffering from distal radius fracture. NVDX3 will be implanted during a single surgical intervention.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDistal Radius Fractures
CountriesLuxembourg
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedAug 14, 2023
Enrollment StartAug 8, 2023
Primary CompletionDec 19, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 2.9 years ago

Interventions

NVDX3drug

NVDX3 is implanted during a single surgical intervention.